ANG Lifesciences Peer Comparison

BSE: 540694

₹33.50

₹0.12 (0.36%)

As on 28-Oct-2026IST

Market cap

₹44 Cr

Revenue (TTM)

₹84 Cr

P/E Ratio

--

P/B Ratio

0.9

Div. Yield

0 %

Edit

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	44	17,958	18,220	17,041	16,318
Revenue (₹ Cr)	84	2,287	1,682	2,570	3,330
Net Profit (₹ Cr)	-13.32	678.07	273.51	735.15	720.77
Net Margin (%)	-15.83	28.10	16.19	26.88	21.60
RoE (%)	-23.81	19.73	11.15	19.16	18.93
Price to Earnings	--	26.99	61.28	23.18	23.06
Price-To-Book	0.90	4.89	6.78	3.87	3.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	83.59	2,287.33	1,682.47	2,569.77	3,329.63
Total Income	84.15	2,413.29	1,689.83	2,735.39	3,337.47
Total Expenditure	85.48	1,490.75	1,203.91	1,628.14	2,168.88
EBITDA	-1.89	796.58	478.55	941.63	1,160.75
Depreciation	6.30	78.10	126.01	57.58	285.40
EBIT	-8.19	718.48	352.55	884.05	875.35
Interest	8.23	0.88	52.11	7.69	187.51
Other Income	0.56	125.96	7.37	165.62	7.84
Exceptional Items	0.00	0.00	12.16	-49.16	-53.14
Profit before Tax	-15.86	843.56	319.96	992.82	642.54
Provision for Tax	-2.54	165.49	46.45	257.67	-78.23
Profit after Tax	-13.32	678.07	273.51	735.15	720.77

Liabilities (₹ Cr)

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	52.89	3,586.42	2,591.20	4,202.90	4,144.34
Minority Interest	0.00	-12.71	0.00	0.00	-10.85
Non-Current Liabilities	7.02	28.74	266.35	91.50	758.48
Current Liabilities	149.04	385.94	848.06	627.48	2,681.14
Total Liabilities	--	3,207.85	3,310.68	4,911.11	6,865.52

Assets (₹ Cr)

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	57.33	1,291.22	2,525.44	770.28	5,578.78
Current Assets	145.12	2,585.66	1,109.77	3,803.22	1,800.86
Total Assets	--	3,207.85	3,310.68	4,911.11	6,865.52
Total Debt*	--	0.55	586.37	2.50	2,421.66
Net Current Assets	-3.92	2,199.72	261.71	3,175.74	-880.28
Contingent Liabilities	--	0.64	76.22	363.79	51.96

Cashflow (₹ Cr)

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	--	432.37	132.27	659.75	1,065.01
Cash Flow from Investing Activities	--	-334.73	-199.13	-71.34	-79.97
Cash from Financing Activities	--	-38.32	62.65	-205.34	-881.32
Net Cash Inflow / Outflow	--	59.32	-4.21	383.07	103.72

Ratios

Profitability Ratios

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	--	26.22	6.95	26.21	13.59
ROE (%)	-23.81	19.73	11.15	19.16	18.93
ROA (%)	-6.08	18.69	7.80	14.95	9.78
EBIT Margin (%)	-9.80	31.41	20.95	34.40	26.29
Net Margin (%)	-15.83	28.10	16.19	26.88	21.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	-15.60	15.01	27.91	10.69	11.06
EBIT Growth (%)	-24.64	18.45	58.32	24.14	13.71
Net Profit Growth (%)	-17.40	19.61	149.56	-9.09	60.98
EPS Growth (%)	-17.40	17.73	-3.57	14.40	80.38
Book Value Growth (%)	--	23.77	30.63	17.30	10.19

Valuation Ratios

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	-3.28	26.99	65.01	22.09	21.36
Price / Book Value	0.90	4.89	6.78	3.87	3.94
Dividend Yield (%)	0.00	0.34	0.06	2.01	0.00
EV/EBITDA	-63.71	21.28	39.35	14.80	15.99
Market Cap (₹ Cr)	--	15,219.80	6,484.12	18,318.10	19,292.77

Solvency Ratios

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.09	0.00	0.07	0.00	0.10
Short term debt to equity ratio	--	0.00	0.13	0.00	0.14
Current Ratio	0.97	6.70	1.31	6.06	0.67
Quick Ratio	0.66	5.59	0.88	5.31	0.49
Interest Coverage	-0.93	959.59	7.14	130.11	4.43

Operating Efficiency Ratios

	ANG Lifesciences	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	81.27	36.10	30.84	7.07	18.98
Asset Turnover	0.38	0.63	0.48	0.52	0.45
Receivable days	--	110.70	118.15	29.10	54.06
Inventory Days	--	65.86	98.29	69.53	32.16
Payable days	--	105.88	128.16	76.77	140.91
Cash Conversion Cycle	--	70.68	88.28	21.86	-54.69

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.